AURA-3 is a phase III clinical study designed to target the secondary EGFR T790M mutation in advanced NSCLC after first-line EGFR-TKI resistance, in which patients were treated with osimertinib- or platinum-based dual drug therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.